Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis open label extension to a double-blind trial

Casilda G. Black, Korn Jh, Marco Matucci‐Cerinic(Vita-Salute San Raffaele University), Frank Krämer(University of Augsburg), Mayes, CP Denton(The Royal Free Hospital), Seibold

UCL Discovery (University College London)

July 1, 2006

Cited by 6

Related Papers

Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

|Unknown|2001|4k

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

|Annals of the Rheumatic Diseases|2003|769

Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis

|JAMA|2014|739

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

|Annals of the Rheumatic Diseases|2009|615

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

|Annals of the Rheumatic Diseases|2010|503